# Huperzine for Cognitive and Functional Impairment in Schizophrenia

> **NCT00963846** · PHASE2 · COMPLETED · sponsor: **Biomedisyn Corporation** · enrollment: 56 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** placebo
- **DRUG:** huperzine 0.2 mg BID
- **DRUG:** huperzine 0.4 mg BID
- **DRUG:** huperzine 0.8 mg BID

## Key facts

- **NCT ID:** NCT00963846
- **Lead sponsor:** Biomedisyn Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2013-03-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00963846

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00963846, "Huperzine for Cognitive and Functional Impairment in Schizophrenia". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00963846. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*